Drug details

Taltz (ixekizumab injection, for subcutaneous use)

type of Interleukin Inhibitors

Taltz (ixekizumab) injection is a humanized interleukin-17A antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

This drug may have the following side effects:

• itching,
• rash,
• fever,
• chills,
• stomach pain,
• cough,
• sore throat,
• severe dizziness, and
• trouble breathing
• swelling of the face, tongue, or throat,
• diarrhea with blood or mucus,

The following drugs are related to Taltz, either as a replacement or used together:

• Soriatane (acitretin)
• Luxiq (betamethasone valerate foam)
• Bryhali (halobetasol propionate lotion)
• Wynzora (calcipotriene and betamethasone dipropionate cream)
• Enstilar (calcipotriene and betamethasone dipropionate foam, 0.005%/0.064%)
• Olux (clobetasol propionate)
• Olux-E (clobetasol propionate foam)
• Cosentyx (secukinumab injection)
• Sotyktu (deucravacitinib tablets)
• Duobrii (halobetasol propionate and tazarotene lotion)
• Raptiva (efalizumab)
• Ultravate X Cream (halobetasol propionate)
• Kimyrsa (oritavancin for injeciton)
• Skyrizi (risankizumab-rzaa injection)
• Zoryve (roflumilast cream)
• Stelara Injection (ustekinumab)
• Vtama (tapinarof cream)